/PRNewswire/ — Halozyme Therapeutics, Inc. (Nasdaq: HALO) (“Halozyme” or the “Company”) today announced that it has entered into a global collaboration and…Read More
Halozyme Announces Global Collaboration and License Agreement with Incyte to Support the Development of Subcutaneous Formulations of INCA033989 Using its ENHANZE® Technology
